Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

赛马鲁肽 医学 安慰剂 危险系数 杜拉鲁肽 内科学 心肌梗塞 不利影响 中止 糖尿病 2型糖尿病 超重 体质指数 临床终点 冲程(发动机) 置信区间 随机对照试验 利拉鲁肽 外科 内分泌学 替代医学 病理 工程类 机械工程
作者
A. Michael Lincoff,Kirstine Brown‐Frandsen,Helen M. Colhoun,John Deanfield,Scott S. Emerson,Sille Esbjerg,Søren Hardt‐Lindberg,G. Kees Hovingh,Steven E. Kahn,Robert F. Kushner,Ildiko Lingvay,Tuğçe Kalaycı Oral,Marie Mide Michelsen,Jorge Plutzky,Christoffer W. Tornøe,Donna H. Ryan
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:389 (24): 2221-2232 被引量:2700
标识
DOI:10.1056/nejmoa2307563
摘要

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
兖州牧完成签到 ,获得积分10
1秒前
不是夏娃完成签到,获得积分10
1秒前
yisun1983完成签到,获得积分10
2秒前
su2589367856完成签到,获得积分10
2秒前
2秒前
丰富如南完成签到,获得积分10
3秒前
Maestro_S的应助被荼蘼采纳,获得10
3秒前
spark完成签到,获得积分10
3秒前
cdercder的应助被YC采纳,获得10
3秒前
涛哥发布了新的文献求助10
3秒前
killGc完成签到,获得积分10
4秒前
刻苦翠丝发布了新的文献求助10
4秒前
chen完成签到,获得积分10
4秒前
Eli发布了新的文献求助10
4秒前
肖鹏完成签到,获得积分10
4秒前
5秒前
shangyu66发布了新的文献求助10
5秒前
5秒前
5秒前
DW的应助被bbkillmm采纳,获得10
5秒前
慕青的应助被Luo采纳,获得10
6秒前
6秒前
CYQ完成签到,获得积分10
6秒前
hu完成签到,获得积分10
6秒前
6秒前
QQ发布了新的文献求助10
7秒前
桃桃发布了新的文献求助10
7秒前
7秒前
8秒前
大眼的平松完成签到,获得积分10
8秒前
机智的紫南完成签到,获得积分10
8秒前
xiaozhang完成签到,获得积分10
8秒前
俏皮沁完成签到,获得积分10
8秒前
li发布了新的文献求助10
8秒前
震动的听安完成签到,获得积分10
8秒前
muxiangrong的应助被wdddd采纳,获得10
9秒前
小不点完成签到,获得积分10
9秒前
Ava的应助被辛勤香岚采纳,获得10
9秒前
方一乔完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174225
求助须知:如何正确求助?哪些是违规求助? 9566274
关于积分的说明 21785725
捐赠科研通 7768401
什么是DOI,文献DOI怎么找? 3431698
关于科研通互助平台的介绍 2555912
邀请新用户注册赠送积分活动 2477007